This was the stock's second consecutive day of losses.

San Francisco observed World AIDS Day with a public program at the National AIDS Memorial Grove in Golden Gate Park.

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...

Gilead Sciences, Inc. GILD entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech ...

Catch up on all the biggest pharma news to hit the industry last month, with stories spanning the US election, new ...

Timely remdesivir treatment in immunocompromised patients infected with COVID-19 is associated with improved survival outcomes.

University of Colorado professor Leslie Leinwand thinks studying python hearts could lead to treatments for human heart disease ...

The stock's fall snapped an eight-day winning streak.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75 ...

The deal with Tubulis will help Gilead regain its footing in the ADC space following the withdrawal of Trodelvy in bladder ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...